Clinical Trial Update: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TQB3616 in combination with Anlotinib or standard chemotherapy for second-line and above advanced lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• TQB3616

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Lung Carcinoma | Phase 2 | Status: TERMINATED